Collplant Holdings (CLGN) has released an update.
CollPlant Holdings and Stratasys have announced the start of a pre-clinical study for 3D printed, regenerative breast implants aimed at a $3 billion market. These implants are designed to promote natural tissue growth and degrade over time, potentially revolutionizing reconstructive and aesthetic breast procedures. The collaboration combines CollPlant’s rhCollagen-based bioinks with Stratasys’ advanced printing technology.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
